Randall Mack is Senior VP & Development at Recro Pharma, Inc. (REPH). They have made 1 open-market trade across 1 company since 2016, most recently 2018-01-18.
CIK 0001602336
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
1 open-market purchase totalling $13K since 2016, never a sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| REPH | 34,713 | $73K |
Shares reported on the most recent Form 4, priced at the 2018-01-22 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| REPH | BUY | 2016-05-23 | 2016-05-25 | $6.30 | $13K | +11.2% | +3.0% | +27.5% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.